Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
22 hours ago • Google News
Xilio Development Inc (XLO)
US$ 0.8285-1.13%
Price Chart
Key Statistics
Market Cap
$ 33.66M
P/E Ratio
0.00
Revenue (TTM)
$ 9.27M
Volume
116.12K
52W High
$ 1.70
52W Low
$ 0.61
Dividend Yield
0.00%
Beta
-0.12
Technicals
50-Day MA
0.7252
200-Day MA
0.8637
52 Week High
1.7
52 Week Low
0.615
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
Employees
64
Headquarters
Waltham, MA
CEO
Dr. Rene Russo BCPS, Pharm.D.
Latest News
Why did XLO's Q4 earnings fall short of forecasts? - AInvest
4 days ago • Google News
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
22 hours ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg